Increased evidence indicating ghrelin's direct influence on bone has been reported, but previous studies did not investigate its relationship with osteonecrosis of the femoral head (ONFH) in vivo. Coagulation disorders are considered to play important roles in ONFH. The aim of this study was to investigate the relationship of ghrelin, von Willebrand Factor (vWF) and other potentially relevant indicators with non-traumatic osteonecrosis of the femoral head.
Methods
Patients with non-traumatic ONFH (including steroid-induced, alcohol-induced, and idiopathic ONFH) and healthy controls were recruited for the study. We evaluated levels of plasma ghrelin and vWF. Other potentially relevant indicators, von Willebrand Factor cleaving protease (vWF-cp), plasminogen activator inhibitor 1 (PAI-1), tissue plasminogen activator (tPA), leptin, C-reactive protein (CRP), and lipid parameters were also assayed. Correlation coefficients and logistic regression models were used to assess the associations.
Results
Patients with non-traumatic ONFH had significantly lower ghrelin levels, higher vWF, PAI-1, CRP levels than those in healthy controls. Ghrelin level was negatively correlated with vWF after adjustment for other variables. Logistic regression model revealed that non-traumatic ONFH was independently associated with plasma ghrelin and vWF.
Conclusions
This study indicates that plasma ghrelin, vWF and PAI-1 levels were changed in patients with non-traumatic ONFH. Ghrelin in combination with vWF may prove to be involved in the pathogenesis of non-traumatic ONFH.
KaushikAPDasACuiQOsteonecrosis of the femoral head: An update in year 2012.World J Orthod. 2012;3(5):49–57.
2.
MotomuraGYamamotoTMiyanishiKJingushiSIwamotoYCombined effects of an anticoagulant and a lipid-lowering agent on the prevention of steroid-induced osteonecrosis in rabbits.Arthritis Rheum. 2004;50(10):3387–3391.
3.
CalderJDButteryLRevellPAPearseMPolakJMApoptosis—a significant cause of bone cell death in osteonecrosis of the femoral head.J Bone Joint Surg Br. 2004;86(8):1209–1213.
4.
YoumYSLeeSYLeeSHApoptosis in the osteonecrosis of the femoral head.Clin Orthop Surg. 2010;2(4):250–255.
5.
Assouline-DayanYChangCGreenspanAShoenfeldYGershwinMEPathogenesis and natural history of osteonecrosis.Semin Arthritis Rheum. 2002;32(2):94–124.
6.
FukushimaNHanadaRTeranishiHGhrelin directly regulates bone formation.J Bone Miner Res. 2005;20(5):790–798.
7.
CoatesPSFernstromJDFernstromMHSchauerPRGreenspanSLGastric bypass surgery for morbid obesity leads to an increase in bone turnover and a decrease in bone mass.J Clin Endocrinol Metab. 2004;89(3):1061–1065.
8.
MaccarinelliGSibiliaVTorselloAGhrelin regulates proliferation and differentiation of osteoblastic cells.J Endocrinol. 2005;184(1):249–256.
9.
KimSWHerSJParkSJGhrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells.Bone. 2005;37(3):359–369.
10.
NapoliNPedoneCPozzilliPEffect of ghrelin on bone mass density: the InChianti study.Bone. 2011;49(2):257–263.
11.
GonnelliSCaffarelliCDel SantoKThe relationship of ghrelin and adiponectin with bone mineral density and bone turnover markers in elderly men.Calcif Tissue Int. 2008;83(1):55–60.
12.
NouhOAbd ElfattahMMHassounaAAAssociation between ghrelin levels and BMD: a cross sectional trial.Gynecol Endocrinol. 2012;28(7):570–572.
13.
Zwirska-KorczalaKKonturekSJSodowskiMBasal and postprandial plasma levels of PYY, ghrelin, cholecystokinin, gastrin and insulin in women with moderate and morbid obesity and metabolic syndrome.J Physiol Pharmacol. 2007;58(Suppl 1):13–35.
14.
DixitVMSchafferEMTaubDDGhrelin is expressed and secreted from human T lymphocytes and inhibits activation and leptin induced inflammatory cytokine expression via functional, lipid raft-associated growth hormone secretagogue receptors (GHS-R).Proceedings of the 85th Annual Meeting of the Endocrine Society. 2003OR 51–53.
15.
JonesJPJrCoagulopathies and osteonecrosis.Acta Orthop Belg. 1999;65(Suppl 1):5–8.
16.
ARCO. Committee on terminology and classification.ARCO News. 1992;4:41–46.
17.
SeamonJKellerTSalehJCuiQThe pathogenesis of nontraumatic osteonecrosis.Arthritis. 2012;2012:601763.
18.
DelhantyPJvan der EerdenBCvan der VeldeMGhrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS-R1a.J Endocrinol. 2006;188(1):37–47.
19.
HudaMSDurhamBHWongSPLack of an acute effect of ghrelin on markers of bone turnover in healthy controls and post-gastrectomy subjects.Bone. 2007;41(3):406–413.
20.
DengFLingJMaJLiuCZhangWStimulation of intramembranous bone repair in rats by ghrelin.Exp Physiol. 2008;93(7):872–879.
21.
Karagiozoglou-LampoudiTTrachanaMAgakidisCGhrelin levels in patients with juvenile idiopathic arthritis: relation to anti-tumor necrosis factor treatment and disease activity.Metabolism. 2011;60(10):1359–1362.
22.
StarklintHLaustenGSArnoldiCCMicrovascular obstruction in avascular necrosis.Immunohistochemistry of 14 femoral heads.Acta Orthop Scand. 1995;66(1):9–12.
23.
JanssonJHNilssonTKJohnsonOvon Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death.Br Heart J. 1991;66(5):351–355.
24.
JanssonJHJohanssonBBomanKNilssonTKHypo-fibrinolysis in patients with hypertension and elevated cholesterol.J Intern Med. 1991;229(4):309–316.
25.
TajtakovaMPetrovicovaJSpurnyPPytliakMPetrasovaDZemberovaESelected hormones levels in individuals with endothelial dysfunction and insulin resistance.Bratisl Lek Listy. 2005;106(1):37–40.
26.
ShimizuYNagayaNTeranishiYGhrelin improves endothelial dysfunction through growth hormone-independent mechanisms in rats.Biochem Biophys Res Commun. 2003;310(3):830–835.
27.
HedayatiNAnnambhotlaSJiangJGrowth hormone-releasing peptide ghrelin inhibits homocysteine-induced endothelial dysfunction in porcine coronary arteries and human endothelial cells.J Vasc Surg. 2009;49(1):199–207.
28.
ZhaoHLiuGWangQEffect of ghrelin on human endothelial cells apoptosis induced by high glucose.Biochem Biophys Res Commun. 2007;362(3):677–681.
29.
ChangLRenYLiuXProtective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart.J Cardiovasc Pharmacol. 2004;43(2):165–170.
30.
KadoglouNPLampropoulosSKapelouzouASerum levels of apelin and ghrelin in patients with acute coronary syndromes and established coronary artery disease—KOZANI STUDY.Transl Res. 2010;155(5):238–246.
31.
VörösKProhászkaZKaszásESerum ghrelin level and TNF-α/ghrelin ratio in patients with previous myocardial infarction.Arch Med Res. 2012;43(7):548–554.
TignoXTSelaruIKAngeloniSVHansenBCIs microvascular flow rate related to ghrelin, leptin and adiponectin levels?Clin Hemorheol Microcirc. 2003;29(3-4):409–416.
34.
LiAChengGZhuGHTarnawskiASGhrelin stimulates angiogenesis in human microvascular endothelial cells: Implications beyond GH release.Biochem Biophys Res Commun. 2007;353(2):238–243.
35.
YuanMJHe-HuangHuHYLi-QuanHong-JiangHuangCXMyocardial angiogenesis after chronic ghrelin treatment in a rat myocardial infarction model.Regul Pept. 2012;179(1-3):39–42.
36.
BobbertPEisenreichAWeithäuserASchultheissHPRauchULeptin and resistin induce increased procoagulability in diabetes mellitus.Cytokine. 2011;56(2):332–337.
37.
OttoBTschöpMHeldweinWPfeifferAFDiederichSEndogenous and exogenous glucocorticoids decrease plasma ghrelin in humans.Eur J Endocrinol. 2004;151(1):113–117.
38.
AkamizuTKangawaKThe physiological significance and potential clinical applications of ghrelin.Eur J Intern Med. 2012;23(3):197–202.
39.
HosodaHKangawaKStandard sample collections for blood ghrelin measurements.Methods Enzymol. 2012;514:113–126.
